Recognizing Gastroparesis While on Ozempic: Key Facts

Latest update (2026-01)

FDA enforcement record (Ongoing): Presence of Particulate Matter: Hair was found in a prefilled syringe. [source]

From General Health Education to Targeted Risk Awareness

If you're taking Ozempic and noticing persistent nausea, vomiting, or feeling full quickly, you may wonder if gastroparesis is the cause. Building on Ebert Clinic's long-standing commitment to evidence-based patient education, this page covers the typical timeline of symptom onset and what you should know about diagnosis and current FDA safety communications.

Understanding Ozempic and Its Link to Gastroparesis

Ozempic, the brand name for semaglutide, is a glucagon-like peptide-1 (GLP-1) receptor agonist approved for the management of type 2 diabetes and, in some formulations, for chronic weight management. Among the adverse effects associated with its use, gastrointestinal complications are prominent and have raised concerns about a potential link to gastroparesis, a condition characterized by delayed gastric emptying without mechanical obstruction. This section examines the clinical presentation of gastroparesis, the pharmacology of Ozempic, reported adverse effects, mechanistic pathways, and risk considerations for affected patients in North Carolina, including settlement-related factors and the statute of limitations. Gastroparesis presents with symptoms such as nausea, vomiting, early satiety, postprandial fullness, bloating, and abdominal pain. Diagnosis typically involves gastric emptying scintigraphy, which measures the rate at which food leaves the stomach. The condition can lead to malnutrition, dehydration, and significant impairment in quality of life. In the context of Ozempic use, gastrointestinal adverse reactions are well-documented. In placebo-controlled trials, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic than placebo (placebo 15.3%, Ozempic 0.5 mg 32.7%, Ozempic 1 mg 36.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). The majority of reports of nausea, vomiting, and/or diarrhea occurred during dose escalation, and more patients receiving Ozempic 0.5 mg (3.1%) and Ozempic 1 mg (3.8%) discontinued treatment due to gastrointestinal adverse reactions than patients receiving placebo (0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). In trials with Ozempic 1 mg and 2 mg, gastrointestinal adverse reactions occurred more frequently among patients receiving Ozempic 2 mg (34.0%) vs Ozempic 1 mg (30.8%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). Additional gastrointestinal adverse reactions with a frequency of less than 5% included dyspepsia (placebo 1.9%, Ozempic 0.5 mg 3.5%, Ozempic 1 mg 2.7%), eructation (0%, 2.7%, 1.1%), flatulence (0.8%, 0.4%, 1.5%), gastroesophageal reflux disease (0%, 1.9%, 1.5%), and gastritis (0.8%, 0.8%, 0.4%) (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). While these data do not specifically list gastroparesis, the spectrum of gastrointestinal symptoms overlaps significantly with gastroparesis presentation.

Mechanistic Pathways and Risk Considerations

The mechanistic pathways linking Ozempic to gastroparesis involve the drug's action on GLP-1 receptors. GLP-1 receptor agonists slow gastric emptying by inhibiting antral contractions and stimulating pyloric tone, which can lead to delayed gastric emptying. This effect is dose-dependent and may become pathological in susceptible individuals, resulting in gastroparesis. The timing of symptom onset is critical; gastrointestinal adverse reactions often occur during dose escalation, suggesting that rapid increases in drug concentration may exacerbate gastric motility issues. The timeline between exposure and documented harm can vary, with some patients experiencing symptoms within weeks of initiation, while others may develop complications after prolonged use. Risk considerations for affected patients in North Carolina include the adequacy of warnings regarding Ozempic and gastroparesis. The prescribing information for Ozempic includes warnings about gastrointestinal adverse reactions but does not explicitly mention gastroparesis. Serious hypersensitivity reactions, such as anaphylaxis and angioedema, have been reported in patients treated with Ozempic, and caution is advised in patients with a history of angioedema or anaphylaxis with another GLP-1 receptor agonist (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166). However, the absence of a specific warning for gastroparesis may be relevant in settlement considerations, as patients could argue that the risk was not adequately communicated.

Statute of Limitations for Ozempic Claims in North Carolina

Settlement-related considerations for affected patients involve the statute of limitations in North Carolina, which generally requires that personal injury claims be filed within three years from the date the injury is discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. The timeline between exposure and documented harm is crucial; if a patient developed symptoms during dose escalation but did not receive a formal diagnosis until months later, the statute of limitations may be affected. Patients should consult with a legal professional to determine their specific deadlines. In summary, the evidence indicates that Ozempic is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis. The mechanistic link through delayed gastric emptying is plausible, and the adequacy of warnings may be questioned. For North Carolina patients, the statute of limitations is a key factor in pursuing settlement, and the timeline from exposure to harm must be carefully documented. References to the prescribing information provide the factual basis for these considerations.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the statute of limitations for Ozempic gastroparesis claims in North Carolina?

In North Carolina, personal injury claims generally must be filed within three years from the date the injury is discovered or should have been discovered. For gastroparesis allegedly caused by Ozempic, the clock may start when the patient is diagnosed or when symptoms become severe enough to prompt medical evaluation. It is important to consult with a legal professional to determine your specific deadline.

Does Ozempic cause gastroparesis?

Ozempic (semaglutide) is associated with a high incidence of gastrointestinal adverse reactions, including symptoms consistent with gastroparesis such as nausea, vomiting, and delayed gastric emptying. While the prescribing information does not explicitly list gastroparesis, the mechanistic link through GLP-1 receptor agonism is plausible. Clinical trials show significantly higher rates of gastrointestinal adverse events in Ozempic users compared to placebo (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=979e4df4-0597-48ea-b51c-0f699fa6d166).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Ozempic exposure and a confirmed Gastroparesis diagnosis may request an independent eligibility review. [Begin Assessment]

References

DailyMed - Ozempic Prescribing Information

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.